Zymfentra, with a price of $6,181.08 for two shots over four weeks, is approved as maintenance therapy for adults with ulcerative colitis and Crohn’s disease.
The market for Humira biosimilars may be shrinking as AbbVie works to boost prescriptions for its next-generation anti-inflammatories, Skyrizi (risankizumab) and Rinvoq (upadacitinib).